Compare SVM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | ORKA |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | SVM | ORKA |
|---|---|---|
| Price | $8.90 | $31.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $9.00 | ★ $48.20 |
| AVG Volume (30 Days) | ★ 5.7M | 647.4K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $323,391,000.00 | N/A |
| Revenue This Year | $22.28 | N/A |
| Revenue Next Year | $32.53 | N/A |
| P/E Ratio | $75.24 | ★ N/A |
| Revenue Growth | ★ 33.99 | N/A |
| 52 Week Low | $2.88 | $5.49 |
| 52 Week High | $9.17 | $32.64 |
| Indicator | SVM | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 66.09 | 59.40 |
| Support Level | $8.37 | $27.84 |
| Resistance Level | $9.17 | $32.64 |
| Average True Range (ATR) | 0.45 | 1.93 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 79.79 | 80.73 |
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.